Human Papillomaviruses, p16\(^{\text{INK4a}}\) and Akt expression in basal cell carcinoma

Francesca Paolini\(^1\), Angelo Carbone\(^1\), Maria Benevolo\(^2\), Vitaliano Silipo\(^3\), Francesca Rollo\(^2\), Renato Covello\(^2\), Paolo Piemonte\(^4,5\), Pasquale Frascione\(^4,5\), Rodolfo Capizzi\(^6\), Caterina Catricalà\(^3\) and Aldo Venuti\(^1\)*

Abstract

**Background:** The pathogenic role of beta-HPVs in non melanoma skin cancer (NMSC), is not still completely understood, and literature data indicate that they might be at least cofactors in the development of certain cutaneous squamous cell carcinomas. However, only few reports contain data on basal cell carcinoma (BCC). The HPVs interact with many cellular proteins altering their function or the expression levels, like the p16\(^{\text{INK4a}}\) and Akt.

Our study aimed to determine the presence of different beta -HPV types and the expression of p16\(^{\text{INK4a}}\) and Akt in BCC, the commonest NMSC, in the normal appearing perilesional skin and in forehead swab of 37 immunocompetent patients.

**Methods:** The expression of p16\(^{\text{INK4a}}\) and Akt, by immunohistochemistry, and the HPV DNA, by nested PCR, were investigated in each sample.

**Results:** No correspondence of HPV types between BCC and swab samples was found, whereas a correspondence between perilesional skin and BCC was ascertained in the 16,7% of the patients. In BCC, 16 different types of beta HPV were found and the most frequent types were HPV107 (15,4%), HPV100 (11,5%) and HPV15 (11,5%) all belonging to the beta HPV species 2. Immunohistochemistry detected significant p16\(^{\text{INK4a}}\) expression in almost all tumor samples (94,3%) with the highest percentages (> 30%) of positive cells detected in 8 cases. A statistically significant (p = 0,012) increase of beta HPV presence was detected in p16\(^{\text{INK4a}}\) strongly positive samples, in particular of species 2. pAkt expression was detected in all tumor samples with only 2 cases showing rare positive cells, whereas Akt2 expression was found in 14 out of 35 BCC (40%); in particular in HPV positive samples over-expressing p16\(^{\text{INK4a}}\).

**Conclusions:** Our data show that p16\(^{\text{INK4a}}\) and pAkt are over-expressed in BCC and that the high expression of p16\(^{\text{INK4a}}\) and of Akt2 isoform is often associated with the presence of beta-HPV species 2 (i.e. HPV 15). The association of these viruses with the up-regulation of p16\(^{\text{INK4a}}\) and Akt/PI3K pathway suggests that in a subtype of BCC these viruses may exert a role in the carcinogenesis or in other, still undefined, biological property of these tumors. If this particular type of BCC reflects a different biology it will remain undisclosed until further studies on a larger number of samples will be performed.

**Keywords:** HPVs, BCC, p16\(^{\text{INK4a}}\) and Akt1/2, skin cancer

**Background**

The family of the Human Papillomaviruses (HPVs) comprises more than 120 different genotypes, 112 (HPV1 to HPV112) of which were characterized after cloning and sequencing of their genomes [1-3]. Currently, HPVs are classified into five genera: Alpha(α)-, Beta (β)-, Gamma (γ)-, Mu(μ)- and Nu(ν)- papillomavirus, according to their genomic DNA sequence [1]. The phylogeny of PVs indicates that these viruses have evolved by multiple mechanisms including, but not exclusively, recombination events between the virus and the corresponding host [4]. Many α-HPVs, in particular HPV 16, can induce papillomatous proliferations with a high risk for malignant progression and are associated with cancer of
the cervix uteri, other anogenital cancers, and a subgroup of head-and-neck squamous cell carcinoma [5-7]. The first link between HPV and skin cancers was demonstrated in a rare autosomal-inherited disease called Epidermodysplasia Verruciformis (EV) [8]. This disease is characterized by an abnormal predisposition to infection by certain HPV types (now classified as the genus β-HPVs) as well as cutaneous lesions that display a high rate of progression to squamous cell carcinoma (SCC). Although genus β-HPVs have been frequently detected in non-melanoma skin cancers (NMSC) in immunosuppressed individuals, very little is known about the presence of the virus in immunocompetent individuals [9-11]. No firm correlation between clinical and pathological NMSC characteristics and HPV DNA prevalence was found. However, it was recently shown that high-risk cutaneous HPV8 early genes enhance tumorigenesis rates in transgenic mice [12], further supporting the hypothesis that β cutaneous HPVs can be tumorigenic [13]. The DNA of these HPV was detected in 30-90% of actinic keratosis and squamous cell carcinomas of non-EV patients [14,15] but few data exist on basal cell carcinoma (BCC), the commonest NMSC. Our study aimed to determine a large spectrum of β-HPV types in BCC of immunocompetent patients by comparing the HPV analysis in the lesional and perilesional skin as well as to investigate whether less invasive technique like forehead swab can be predictive of the HPV presence in skin tumors.

In addition, in order to evaluate the role of β-HPV in neoplastic proliferation, the expression of two host genes, p16INK4a and Akt, were investigated. The expression pattern of p16INK4a in dysplastic squamous and glandular cervical cells in tissue sections and in cervical smears has been extensively investigated and linked [16,17] to anogenital α-HPV gene expression. The same α-HPVs are also able to interact with the Akt pathway [18]. Cutaneous HPVs can modulate epidermal Akt activity using the same mechanisms as anogenital HPVs with the differences that β-HPV downregulates the Akt1 during infection and do not affect the up-regulation of the Akt2 isofrom during cancerogenesis. Indeed Akt activity is associated with stratum corneum function [19], and it was reported that cutaneous HPVs also modulate stratum corneum properties acting through Akt1 down-regulation.

However few data reported the involvement of β HPV, p16INK4a and Akt expression in BCC and therefore in the present study their possible relationships were investigated.

Methods

Patients

The patients enrolled in the study were attending Department of Dermatology-Oncology of San Gallicano Institute (IRCCS) of Rome, Italy. This study was approved by the local medical ethical committee and patients signed an informed consent. In brief all patients answered a standardized interview and underwent a physical examination. During physical examination, the dermatologist recorded the skin type (Fitzpatrick’s Scale), the possible presence of skin cancers and their anatomical localization (Table 1). Only the patients with histological confirmed skin cancer were further evaluated. In brief, 37 paraffin-embedded blocks, microscopically diagnosed as BCC by expert pathologists were analyzed at the Regina Elena National Cancer Institute (IRCCS) of Rome, Italy. Safe margin was defined as a part of perilesional skin that had no evidence of involvement by BCC. This group was considered as controls. In addition, from the same patients material by forehead swab was obtained, recovered in 1 ml of preservCyt medium (Cytyc Corp., Rome, Italy), and stored at 4°C until analysed.

DNA isolation from different sample types

Ten-micron sections were prepared from paraffin blocks and were stored in sterile tubes. Chances of contamination during section cutting were minimized by removing the initial section that was cut to remove any environmental contamination which had occurred while blocks were stored and by changing cryostat blades in between samples. In the tubes containing the sections 1,2 mL of xylene were added to remove the paraffin, subsequently the tubes were centrifuged at high speed for 1 minute and the liquid layer was removed. The pellet was suspended in 1,2 mL of 100% ethanol and after high-speed centrifugation the supernatant was discarded. If necessary, a second ethanol wash was performed. Next, the pellet was processed by the QIAamp DNA Mini kit (QIAGEN, Milan, Italy) according to the manufacturer’s instructions. Swab samples stored in preservCyt medium were centrifuged and the DNA was extracted with the same QIAMP DNA mini kit. The final elution was performed in 100 µL of tris/EDTA buffer.

HPV DNA detection by PCRs

HPV DNA detection was carried out using the primers located in the late L1 ORF as previously described. Briefly, CP65/70 [11] and MY09/11 [20] primers were utilized in the first PCR and CP66/69 [11] and GP5+/6+ [21] for the nested PCR. The quality of the isolated DNA was checked by amplifying β-globin gene [22]. Five µL of purified DNA was used in each PCR mixture. In short, the PCR assay was carried out in a 50-µL mixture containing the primer sets at 25 pmol each, 3.6 mM MgCl2, a mixture of deoxynucleoside triphosphates 2.5 mM each and 1 U of Taq polymerase (Invitrogen, Italy). Cycling conditions were as follows: 2.30 min of
Table 1 Molecular analysis of BCC

| Patient | Gender | Age | Phototype Fitzpatrick’s Scale | Anatomic site | HPV affecting forehead | HPV lesion | HPV normal skin | p16\textsuperscript{ink4a} lesion | p-Akt lesion | Akt2 lesion |
|---------|--------|-----|-------------------------------|---------------|-----------------------|-----------|----------------|----------------|--------------|------------|
| 1       | M      | 89  | III                           | Back          | DL231                 | HPV 107   | neg            | Moderate (1%)  | ND           | ND         |
| 2       | M      | 47  | II                            | Back          | HPV 36                | HPV 38    | neg            | Moderate (10%) | ND           | ND         |
| 3       | M      | 68  | III                           | Back          | DL231                 | HPV 99    | neg            | Moderate (10%) | neg          | neg        |
| 4       | M      | 70  | II                            | Back          | 113                   | DL231     | neg            | Moderate (5%)  | positive      | neg        |
| 5       | F      | 76  | II                            | Legs          | HPV 38                | neg       | HPVX14         | Moderate (20%) | positive      | neg        |
| 6       | M      | 64  | II                            | Back          | HPV 38                | HPV 107   | neg            | High (30%)     | positive      | positive    |
| 7       | F      | 76  | III                           | Legs          | HPV 47                | HPV 15    | HPV 38         | High (40%)     | positive      | positive    |
| 8       | F      | 76  | III                           | Back          | HPV 47                | DL473     | HPV 38         | Moderate (15%) | positive      | neg        |
| 9       | F      | 78  | III                           | Back          | HPV 100               | HPV 8     | HPV 38         | Moderate (10%) | positive      | positive    |
| 10      | M      | 80  | III                           | Back          | neg                   | HPV 15    | HPV 15         | High (30%)     | positive      | neg        |
| 11      | M      | 44  | IV                            | Trunk         | HPV 100               | HPV 15    | HPV 15         | High (40%)     | positive      | positive    |
| 12      | M      | 82  | III                           | Trunk         | HPV 98                | HPV 8     | HPV 8          | Moderate (1%)  | positive      | neg        |
| 13      | F      | 37  | III                           | Trunk         | DL314                 | HPV 24    | HPV 38         | Moderate (3%)  | positive      | neg        |
| 14      | F      | 61  | IV                            | Trunk         | 100                   | HPV 24    | DL314          | Moderate (15%) | positive      | positive    |
| 15      | M      | 76  | III                           | Legs          | HPV 113               | neg       | neg            | Moderate (4%)  | positive      | neg        |
| 16      | M      | 56  | III                           | Trunk         | HPV 5                 | neg       | DL 231         | Moderate (1%)  | ND           | neg        |
| 17      | M      | 58  | III                           | Head          | HPV 15                | neg       | neg            | Moderate (2%)  | ND           | neg        |
| 18      | M      | 68  | III                           | Neck          | HPV 115               | neg       | HPV 38         | Moderate (20%) | positive      | positive    |
| 19      | F      | 67  | IV                            | Arms           | HPVX14                | HPV 107   | HPV 8          | neg            | positive      | positive    |
| 20      | M      | 71  | II                            | Trunk         | DL267                 | neg       | neg            | ND             | positive      | neg        |
| 21      | M      | 80  | IV                            | Forehead      | HPVX14                | HPV 115   | HPV 113        | Moderate (10%) | positive      | positive    |
| 22      | M      | 45  | II                            | Trunk         | HPV 15                | HPV 100   | HPV 107        | Moderate (1%)  | positive      | positive    |
| 23      | F      | 40  | III                           | Arms           | HPV 24                | HPV 100   | neg            | Moderate (10%) | positive      | neg        |
| 24      | F      | 50  | II                            | Back           | HPVX14                | HPV 122   | neg            | ND             | ND           | positive    |
| 25      | M      | 80  | IV                            | Trunk         | HPV 37                | HPV 107   | neg            | Moderate (20%) | positive      | positive    |
| 26      | F      | 69  | II                            | Neck          | HPV 23                | DL267     | neg            | High (30%)     | positive      | positive    |
| 27      | M      | 51  | IV                            | Legs           | DL267                 | neg       | neg            | neg            | negative      | negative    |
| 28      | M      | 61  | IV                            | Back           | neg                   | neg       | neg            | High (40%)     | positive      | positive    |
| 29      | F      | 71  | IV                            | Forehead       | HPV 100               | HPV 20    | neg            | Moderate (15%) | positive      | neg        |
| 30      | M      | 45  | IV                            | Back           | neg                   | HPV 100   | HPVX14         | High (50%)     | positive      | neg        |
| 31      | M      | 39  | II                            | Back           | HPV 100               | HPV 20    | HPVX14         | Moderate (5%)  | positive      | negative    |
| 32      | F      | 41  | III                           | Trunk         | HPV 151               | HPVX14    | neg            | Moderate (3%)  | positive      | positive    |
| 33      | F      | 60  | III                           | Back           | HPV 38                | neg       | DL267          | Moderate (20%) | positive      | neg        |
| 34      | F      | 69  | III                           | Back           | HPV 38                | neg       | neg            | Moderate (5%)  | positive      | neg        |
| 35      | F      | 60  | III                           | Back           | HPV 38                | neg       | DL267          | Moderate (5%)  | positive      | neg        |
| 36      | M      | 39  | II                            | Back           | HPV 100               | HPV 113   | HPVX14         | Moderate (15%) | positive      | neg        |
| 37      | F      | 40  | III                           | Arms           | HPV 24                | HPV 151   | HPV 107        | High (30%)     | positive      | neg        |

ND, not done.
denaturation at 95°C, followed by 40 cycles of 1 min of
denaturation at 95°C, 1.5 min of annealing at 50°C
(CP65/70 and GP5+/6+) or 55°C (CP66/69 and MY09/
11), and 2 min of extension at 72°C. An additional incu-
bation for 10 min at 72°C was performed at the end of
cycling. All temperature transitions were performed with
maximal heating and cooling settings (5°C/s). For every
PCRs, a reaction negative control (sterile water only) was
included. These controls were processed in the same way
as the tissue specimens and they were never found to be
positive for HPV. Twenty μL aliquot of the PCR mixture
was visualized by ethidium bromide staining after agarose
gel electrophoresis. The amplified products were purified,
and sequenced in an automated apparatus (BioFab,
Rome, Italy). The determination of specific genotypes
were done analyzing the sequences with BLAST pro-
gramme (http://www.ncbi.nlm.nih.gov/BLAST).

p16INK4a, p-Akt and Akt2 immunohistochemistry
The p16INK4a, p-Akt and Akt2 immunostaining was car-
ried out on 5 μm thick sections from formalin fixed par-
affin embedded blocks.
p-Akt and Akt2 immunohistochemistry was performed
using the rabbit monoclonal antibodies Ser473 and 54G8
(Cell Signaling, SIAL, Rome, Italy), respectively. Antigen
retrieval was carried out by pretreating the dewaxed and
rehydrated slides in a water bath at 96°C for 40 minutes
in sodium citrate buffer (citric acid monohydrate 10 mM
adjusted to pH 6.0 with 2 N sodium hydroxide), followed
by cooling at room temperature for both antibodies.
Immunoreactivity was revealed by means of a super sen-
sitive multilink streptavidin-enhanced immunoperoxidase
system (Novocastra, Menarini, Florence, Italy), using 3,3’-
diaminobenzidine as a chromogenic substrate. p16INK4a
expression was revealed by means of a commercially
available kit (CINTec Histology Kit, Mtm, Italy), which
includes the monoclonal antibody E6H4, following the
manufacturer’s instructions.

Scoring of the p16INK4a immunostaining
Nuclear stain, with or without cytoplasmic reactivity,
was considered positive and a percentage of positive
nuclei was calculated. Samples were then divided in
three categories according to the number of p16INK4a
-positive atypical keratinocytes: negative (< 1% positive
nuclei), moderate: less than 30% positive nuclei, and
strong: 30% or more positive nuclei. Similar scoring was
already employed to ascertain p16INK4a expression in
NMSC [23]. Staining intensity was not graded to avoid
subjective interpretation.

Scoring of the Akt immunostaining
Cases were considered positive for p-Akt and Akt2
when cytoplasmic as well as nuclear staining was strong
and clearly different from that of the surrounding nor-
mal epithelium, independently of the number of positive
cells [24]. Staining intensity was not graded to avoid
subjective interpretation.

Results and discussion
HPV DNA in different specimens
Thirty-seven immunocompetent patients referred to the
Dermatology Clinic at San Gallicano Institute and
affected by BCC were included in the study. The mean
age was 62 ± 15 years. Data for each patient are
reported in Table 1. Ten and fifteen BCC were from the
trunk and back respectively, 7 from the extremities and
5 from the head and neck region. Each bioptic skin
sample underwent to immunohistochemical analysis and
HPV nested PCR on consecutive slices. In all samples
the HPV DNA was detected in 26 of 37 (70.3%) lesional
skins and in 19 of 37 (51.3%) perilesional areas. No alpha
or gamma papillomavirus was detected. Forehead swabs
showed positivity for beta-HPV in 34 of 37 (91.9%) sam-
ples. Similar proportions of HPV positive forehead sam-
ples were already described in individuals with skin
cancer [25,26]. No statistically significant association
was revealed among HPV presence, phototype, or anato-
mal localization. Among the detected papillomaviruses
in all analyzed samples, HPV38 was the most frequent
type (Figure 1).

Figure 1 HPV typing. HPV types were detected as in Methods and
are reported as number of positive samples for each type in all
analysed specimens.
In the HPV DNA-positive BCC samples, 16 different types of beta-HPV were found and the most frequent types were HPV107 (15.4%), HPV100 (11.5%) and HPV15 (11.5%) all belonging to the β-HPV species 2, while in perilesional samples the different HPV types detected were 9 and the most frequent was the HPV38 (26.3%) (Figure 2). Forslund et al [27] found that in sun-exposed skin, cutaneous species 2 HPVs were predominating in SCC. Although the number of specimens analyzed in this study is not suitable to state the prevalence rate of HPV species, our data can lead to hypothesize a correlation between beta-HPV species 2 and BCC. However some serological studies showed no firm association of both cutaneous and genital HPV with BCC [28,29].

The HPV types found in forehead swabs were 18 and the most frequent type was HPV100 (17.6%). No correspondence of HPV type between BCC and swab samples was found, whereas a correspondence between perilesional normal skin and BCC was found in three samples (Table 1). Rollison et al. [30] evaluating BCC patients reported that HPV DNA in the cutaneous swabs of normal skin was a poor specific marker to predict the HPV type in the tumor tissue. However, specificity improved when combinations of different biomarkers were evaluated, especially among SCC cases [31]. In our study only a single non-invasive technique was employed and the results confirm that cutaneous swabs cannot be utilized as a single method for epidemiological studies on HPV associated skin cancer.

**Immunohistochemistry analysis**

**p16INK4a immunostaining**

Immunohistochemistry detected p16INK4a expression in 33 of 35 (94.2%) tumor samples. In particular a higher score (≥ 30% of p16INK4a positive dysplastic keratinocytes) was detected in 8 cases (Table 1 and Figure 3). Absent or weak p16INK4a expression was documented in rare cells of few perilesional skin samples (Figure 3).

These data contrast with those showing that an inactivation of p16INK4a is commonly associated with more malignant features in many tumors [31], including BCC [32-37]. However other reports stated a strong p16INK4a mRNA expression in BCC skin [38-40]. Eshkoor et al. [39] found a significant protein and mRNA expression in BCC cells when compared with normal skin tissue. In particular the samples they tested were paraffin-embedded skin BCC as our samples. Indeed conflicting results could be attributed to different methods used, which need further optimization of experimental conditions. Furthermore, there appears to be a strong relationship between the level of invasiveness and expression of p16INK4a. Svensson et al. [40] showed that p16INK4a expression is associated with a highly invasive BCC subtype with infiltrative growth patterns. In the mean time the results of Conscience et al. [38] contradict those of Svensson et al. [40], as they did not observe any difference in the expression of p16INK4a among different histological types of carcinoma suggesting that p16INK4a expression does not correlate with malignancy or proliferation. On the contrary the p16INK4a over-expression was found significantly associated with the BCC location on sun-exposed areas. Our data did not evidence such association and are more consistent with those of Eshkoor et al. [39] and Svensson et al. [40].

**Akt 1/2 immunostaining**

Immunohistochemistry detected pAkt1 expression in 30 out of 32 (93.7%) tumor samples (Table 1 and Figure 4).
with only 2 cases showing rare positive cells. Most of the positive cells showed signal in the cytoplasm and in the nucleus, suggesting that pAkt properly translocates in the nucleus to exert its activity. Thus the PI3K/Akt pathway is activated in BCC examined in our study.

This result suggests that activation of this important pathway is involved in the pathogenesis of non-melanoma skin cancer. Similar observations have been reported previously. In one study, 11 SCC and 17 BCC were stained for pAkt and both tumors showed expression of pAkt [41]. Another immunohistochemical study included 50 SCC and 20 BCC and found also a higher pAkt expression in SCC than in BCC [42]. Finally in a recent report including 30 SSC and 31 BCC no significant difference regarding pAkt expression was detected between SCC and BCC even though all BCC showed positive signal for pAkt in immunohistochemistry [43]. Therefore, our immunohistochemical results confirm previous reports about the role of the PI3K/Akt signaling pathway in the pathogenesis of non-melanoma skin cancer, including BCC. However, it was reported that Akt1 isoform may be down-regulated in human SCC, while Akt2 isoform is up-regulated in most cases [13]. This increased phosphorylation of pAkt in NMSC may be caused by activating mutations of Akt2, but these mutations appear to be very infrequent events with no
On the contrary, experimental evidences indicate that Akt2 up-regulation occurs mostly in the β-HPV/+ve tumor [13]. Therefore, the detected increased phosphorylation of pAkt in our BCC may be also caused by beta-HPV induced activation of Akt2. Indeed Akt2 expression was detected in 14 out of 35 BCC (40%) and in particular in samples in which the presence of beta HPV was associated with an over expression of p16INK4a (Table 1 and Figure 3).

**HPV, p16INK4a, and Akt**

Many studies investigated the correlation between HPV infection and skin tumor pathogenesis but so far HPV types with a putative increased malignant potential have been observed mostly only in SCC, in a few EV patients and in some cases of NMSC of immunosuppressed transplant recipients. Data on the relationship between BCC and HPV infection are still not consistent with a causative role. Nevertheless our data indicate an association between β-HPV and the expression of p16INK4a and Akt that are involved in cell cycle deregulation.

The immunohistochemistry data showed the activation of Akt/Pi3K pathway in BCC and literature data suggest that HPV can interact with this pathway by activating the isoform Akt2 [13,42]. The simultaneously up-regulation of p16INK4a may reflect the interaction of E7 oncoprotein of β-HPV species 2 with pRb, with a mechanism similar to that already reported for α-HPV [16]. Indeed recent reports indicate that the E7 protein of β HPV may interact in vitro with pRb (Cornet I., personal communication) causing an elevation of p16INK4a expression. In particular we detected and defined the expression of p16INK4a as moderate with less than 30% positive keratinocytes or high with 30% or more positive cells. As shown in Figure 5, on the basis of this cut-off, a statistically significant (Fisher’s exact test; \(p = 0.012\)) difference in the percentage (88% versus 68%, respectively) of HPV positive samples was detected between high and moderate p16INK4a positive samples, indicating that an association may exist between β-HPV and BCC. A direct link will be proved in further studies by detecting the co-localization of beta-HPV expression and p16INK4a in dysplastic cells.

In alternative the up-regulation of Akt2 and p16INK4a in some samples may be indicative of the presence of an active β-HPV and may represent surrogate markers of viral infection without a direct involvement into carcinogenesis.

**Conclusions**

Our data demonstrate that p16INK4a and pAkt are over-expressed in BCC and that this high expression of p16INK4a and of the Akt2 isoform is associated with the presence of β-HPV species 2 (i.e. HPV 15). Our study was not performed to give information about prevalence of HPV, therefore the results cannot be considered for the identification of putative high risk beta papillomavirus. Nevertheless, the association of these viruses with the up-regulation of p16INK4a and Akt/Pi3K pathway suggests that in a subtype of BCC these viruses may exert a role in the carcinogenesis or in other, still undefined, biological property of these tumors. If this particular type of BCC reflects a different biology it will remain undisclosed until further studies on a larger number of samples will be performed.
List of abbreviations used

(HPV): Human Papillomaviruses; (EV): Epidermodysplasia Verruciformis; (NMSC): Non-melanoma skin cancers; (SCC): Squamous cell carcinoma; (BCC): Basal cell carcinoma

Acknowledgements

Work partially supported by Lega Italiana Lotta Tumori (LILT). FP and AC are recipient of fellows by LILT. We thank Valerio Antonini for the help in the graphic art.

Author details

1Laboratory of Virology, Regina Elena National Cancer Institute, Rome, Italy.
2Department of Pathology, Regina Elena National Cancer Institute, Rome, Italy.
3Department of Dermatology-Oncology, S. Gallicano Dermatological Institute, Rome, Italy.
4SSD Dermatology, Regina Elena National Cancer Institute, Rome, Italy.
5Current address: Department of Dermatology-Oncology, S. Gallicano Dermatological Institute, Rome, Italy.
6Department of Dermatology, Catholic University of the Sacred Heart, Rome, Italy.

Authors’ contributions

FP performed PCR analysis, participated in data acquisition and drafted the manuscript; AC performed data acquisition and clinical analysis, participated in PCR analysis and drafted the manuscript; MB helped to draft the manuscript and supervised the immunohistochemical analysis; VS participated in the study design, in data acquisition and in clinical analysis; FR performed immunohistochemical analysis, RC performed histological analysis, PP participated in the data acquisition and in clinical analysis; PF participated in the data acquisition and in clinical analysis; RC participated in the study design; CC participated in the study design and coordination; finally, AV conceived of the study, participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Authors’ information

CC is head of Department of Dermatology-Oncology, S. Gallicano Dermatological Institute, Rome, Italy. AV is Acting Chief of the Laboratory of Virology Regina Elena National Cancer Institute, Rome, Italy.

Competing interests

The authors declare that they have no competing interests.

Received: 13 October 2011 Accepted: 14 November 2011 Published: 14 November 2011

References

1. Bernard H-U, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, et al: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401:76-79.
2. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology 2004, 324:17-27.
3. Bravo IG, Alonso A: Phylogeny and evolution of papillomaviruses based on the E1 and E2 proteins. Vitas Genes 2007, 3:249-262.
4. Gottschling M, Stamatakis A, Nindl I, Stockfleth E, Alonso A, Bravo IG: Multiple evolutionary mechanisms drive papillomavirus diversification. Mol Biol Evol 2007, 24:1292-1296.
5. zur H, Hausen A: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2:342-350.
6. Badaracco G, Rizzo C, Mafera B, Pichi B, Giannarelli D, Rahimi SS, Vgili MG, Vennuti A: Molecular analyses and prognostic relevance of HPV in head and neck tumors. Oncol Rep 2007, 17:931-939.
7. Vennuti A, Badaracco G, Rizzo C, Nattino B, Rahimi S, Vgili MG: Presence of HPV in head and neck tumors: high prevalence in tonsillar localization. J Exp Clin Cancer Res 2004, 23:561-566.
8. Vennuti A: Genetics of epidermodysplasia verruciformis: insights into host defense against papillomaviruses. Semin Immunol 2006, 18:362-374.
9. Harwood CA, Suenthenrattan T, Mcgegor JM, Spink PJ, Leigh IM, Breuer J, Proby CM: Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000, 61:289-297.
10. Forslund O, Antonsson A, Nordin P, Stenquist B, Hansson BG: A broad range of human papillomavirus types detected with a general PCR

method suitable for analysis of cutaneous tumors and normal skin. J Gen Virol 1999, 80:2437-2443.
11. Berdhoult RJ, Tieben LM, Smits HL, Bavinck JN, Vermeer B, ter Schegget J: Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J Clin Microbiol 1995, 33:690-695.
12. Schaper ID, Marucuzzi GP, Weissenborn SJ, Kasper HU, Dries V, Smyth N, Fuchs P, Pfister H: Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8. Cancer Res 2005, 65:1394-1400.
13. O’Snaithnesy RF, Akgül B, Storey A, Pfister H, Harwood CA, Byrne C: Cutaneous human papillomaviruses down-regulate AKT1, whereas AKT2 up-regulation and activation associates with tumors. Cancer Res 2007, 67:8207-8215.
14. Patel AS, Karagas MR, Perry AE, Nelson HH: Exposure profiles and human papillomavirus infection in skin cancer: an analysis of 25 genus-beta- types in a population-based study. J Invest Dermatol 2008, 128:2888-2893.
15. Zaravinos A, Kanellou P, Spandides D: Viral DNA detection and RAS mutations in actinic keratosis and non melanoma skin cancers. Br J Dermatol 2010, 162:325-331.
16. Knae W, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dallenbach-Hellweg G, Schmidt D, von Knebel Doeberitz M: Overexpression of p16INK4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001, 92:276-284.
17. Benevolo M, Mottolese M, Marandino F, Vucaturo G, Sindico R, Ripper G, Manari L, Spreuti I, Canali P, Donnorso RP, Vucaturo A: Immunohistochemical expression of p16INK4A is predictive of HR-HPV infection in cervical low-grade lesions. Mod Pathol 2006, 19:384-91.
18. Menges CW, Baglia LA, Lappoo R, Mccarne DJ: Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblasotoma pathway. Cancer Res 2006, 66:5555-5559.
19. O’Snaithnesy RF, Welti JC, Cooke JC, Avilion AA, Monks B, Birmbaum MJ, Byrne C: AKT-dependent Hsp81 (Hsp27) activity in epithelial development. J Biol Chem 2007, 282:17297-17305.
20. Manso MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM: Use of polymerase chain reaction amplification for the detection of genital human papillomavirus. Cancer Cells 1989, 7:209-214.
21. Jacobs MV, Snyder PJ, van den Brule AJ, Helmerhorst TJ, Meijer J, Walboomers JM: A general primer GP5(+)/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 highrisk and 6 low-risk human papillomaviruses genotypes in vaginal scrapings. J Clin Microbiol 1997, 35:791-795.
22. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA: Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988, 239:487-491.
23. Nindl I, Meyer T, Schmook T, Ulrich C, Ridder R, Auditing H, Sterry W, Stockfleth E: Human papillomavirus and overexpression of p16INK4a in nonmelanoma skin cancer. Dermatol Surg 2004, 30:409-414.
24. Pérez-Tenorio G, Stål O, Southeast Sweden Breast Cancer Group: Activation of AKT1/PI3K in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002, 86:540-545.
25. Boxman IL, Russell A, Mulder LH, Bavinck JN, Schegget J, Meijer J, Wallboomers JM: A general primer GP5(+)/GP6(+) mediated PCR enzyme immunoassay method for rapid detection of 14 highrisk and 6 low-risk human papillomaviruses genotypes in vaginal scrapings. J Clin Microbiol 1997, 35:791-795.
patients with a previous nonmelanoma skin cancer. Br J Dermatol 2011, 165:782-91.

30. Rollison DE, Pawlita M, Giuliani AR, Iannacone MR, Sondak VK, Messina JL, Cruse CW, Fenske NA, Glass LF, Kienstra M, Michael KM, Waterboer T, Gheit T, Tommasino M: Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers. Int J Cancer 2008, 123:2337-42.

31. Sherr CJ: Cancer cell cycles. Science 1996, 274(5293):1672-7, Review.

32. Bianchi AB, Fischer SM, Robles AI, Rinchik EM, Conti CJ: Overexpression of cyclin D1 in mouse skin carcinogenesis. Oncogene 1993, 8:1127-33.

33. Yamamoto H, Ochiya T, Takeshita F, Tampiona-Baba H, Hirai K, Sasaki H, Sasaki H, Sakamoto H, Yoshida T, Saito I, Terada M: Enhanced skin carcinogenesis in cyclin D1-conditional transgenic mice: cyclin D1 alters keratinocyte response to calcium-induced terminal differentiation. Cancer Res 2002, 62:1641-7.

34. Sauter ER, Nesbit M, Watson JC, Klein-Szanto A, Litwin S, Herlyn M: Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res 1999, 59:4876-81.

35. Nindl I, Meyer T, Schmook T, Ulrich C, Ridder R, Audring H, Steery W, Stockfleth E: Human papillomavirus and overexpression of P16 INK4a in nonmelanoma skin cancer. Dermatol Surg 2004, 30:409-14.

36. Nilsson K, Svensson S, Landberg G: Retinoblastoma protein function and p16 INK4a expression in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma of the skin and links between p16 INK4a expression and infiltrative behavior. Mod Pathol 2004, 17:1464-74.

37. Concience I, Jovenin N, Coissard C, Lorenzato M, Durlach A, Grange F, Birembaut P, Clavel C, Bernard P: P16 is overexpressed in cutaneous carcinomas located on sun-exposed areas. Eur J Dermatol 2006, 16:518-22.

38. Lin N, Moroi Y, Uchi H, Fukwake N, Danichi T, Takeuchi S, Takahara M, Tu Y, Furue M, Urabe K: Significance of the expression of phosphorylated-STAT3, -Akt, and -ERK1/2 in several tumors of the epidermis. J Dermatol Sci 2007, 48:71-73.

39. Dutt A, Salvesen HB, Greulich H, Sellers WR, Beroukhim R, Meyerson M: Somatic mutations are present in all members of the AKT family in endometrial carcinoma. Br J Cancer 2009, 101:1218-1219.

40. Soung YH, Lee JW, Nam SW, Lee JY, Yoo NJ, Lee SH: Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. Oncology 2006, 70:285-289.

41. Kim MS, Jeong EG, Yoo NJ, Lee SH: Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 2008, 98:1533-1535.